255 related articles for article (PubMed ID: 18854490)
1. First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates.
Sankaranarayanan S; Holahan MA; Colussi D; Crouthamel MC; Devanarayan V; Ellis J; Espeseth A; Gates AT; Graham SL; Gregro AR; Hazuda D; Hochman JH; Holloway K; Jin L; Kahana J; Lai MT; Lineberger J; McGaughey G; Moore KP; Nantermet P; Pietrak B; Price EA; Rajapakse H; Stauffer S; Steinbeiser MA; Seabrook G; Selnick HG; Shi XP; Stanton MG; Swestock J; Tugusheva K; Tyler KX; Vacca JP; Wong J; Wu G; Xu M; Cook JJ; Simon AJ
J Pharmacol Exp Ther; 2009 Jan; 328(1):131-40. PubMed ID: 18854490
[TBL] [Abstract][Full Text] [Related]
2. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
[TBL] [Abstract][Full Text] [Related]
3. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
[TBL] [Abstract][Full Text] [Related]
4. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.
Sankaranarayanan S; Price EA; Wu G; Crouthamel MC; Shi XP; Tugusheva K; Tyler KX; Kahana J; Ellis J; Jin L; Steele T; Stachel S; Coburn C; Simon AJ
J Pharmacol Exp Ther; 2008 Mar; 324(3):957-69. PubMed ID: 18156464
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo.
Elvang AB; Volbracht C; Pedersen LØ; Jensen KG; Karlsson JJ; Larsen SA; Mørk A; Stensbøl TB; Bastlund JF
J Neurochem; 2009 Sep; 110(5):1377-87. PubMed ID: 19519664
[TBL] [Abstract][Full Text] [Related]
6. Rapid P1 SAR of brain penetrant tertiary carbinamine derived BACE inhibitors.
Zhu H; Young MB; Nantermet PG; Graham SL; Colussi D; Lai MT; Pietrak B; Price EA; Sankaranarayanan S; Shi XP; Tugusheva K; Holahan MA; Michener MS; Cook JJ; Simon A; Hazuda DJ; Vacca JP; Rajapakse HA
Bioorg Med Chem Lett; 2010 Mar; 20(5):1779-82. PubMed ID: 20122828
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
Abramowski D; Wiederhold KH; Furrer U; Jaton AL; Neuenschwander A; Runser MJ; Danner S; Reichwald J; Ammaturo D; Staab D; Stoeckli M; Rueeger H; Neumann U; Staufenbiel M
J Pharmacol Exp Ther; 2008 Nov; 327(2):411-24. PubMed ID: 18687920
[TBL] [Abstract][Full Text] [Related]
8. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
[TBL] [Abstract][Full Text] [Related]
9. Establishing the relationship between in vitro potency, pharmacokinetic, and pharmacodynamic parameters in a series of orally available, hydroxyethylamine-derived β-secretase inhibitors.
Wood S; Wen PH; Zhang J; Zhu L; Luo Y; Babu-Khan S; Chen K; Pham R; Esmay J; Dineen TA; Kaller MR; Weiss MM; Hitchcock SA; Citron M; Zhong W; Hickman D; Williamson T
J Pharmacol Exp Ther; 2012 Nov; 343(2):460-7. PubMed ID: 22911925
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic pharmacokinetic-pharmacodynamic modeling of BACE1 inhibition in monkeys: development of a predictive model for amyloid precursor protein processing.
Liu X; Wong H; Scearce-Levie K; Watts RJ; Coraggio M; Shin YG; Peng K; Wildsmith KR; Atwal JK; Mango J; Schauer SP; Regal K; Hunt KW; Thomas AA; Siu M; Lyssikatos J; Deshmukh G; Hop CE
Drug Metab Dispos; 2013 Jul; 41(7):1319-28. PubMed ID: 23584887
[TBL] [Abstract][Full Text] [Related]
11. Spirocyclic β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors: from hit to lowering of cerebrospinal fluid (CSF) amyloid β in a higher species.
Hunt KW; Cook AW; Watts RJ; Clark CT; Vigers G; Smith D; Metcalf AT; Gunawardana IW; Burkard M; Cox AA; Geck Do MK; Dutcher D; Thomas AA; Rana S; Kallan NC; DeLisle RK; Rizzi JP; Regal K; Sammond D; Groneberg R; Siu M; Purkey H; Lyssikatos JP; Marlow A; Liu X; Tang TP
J Med Chem; 2013 Apr; 56(8):3379-403. PubMed ID: 23537249
[TBL] [Abstract][Full Text] [Related]
12. From fragment screening to in vivo efficacy: optimization of a series of 2-aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1).
Cheng Y; Judd TC; Bartberger MD; Brown J; Chen K; Fremeau RT; Hickman D; Hitchcock SA; Jordan B; Li V; Lopez P; Louie SW; Luo Y; Michelsen K; Nixey T; Powers TS; Rattan C; Sickmier EA; St Jean DJ; Wahl RC; Wen PH; Wood S
J Med Chem; 2011 Aug; 54(16):5836-57. PubMed ID: 21707077
[TBL] [Abstract][Full Text] [Related]
13. Characterization of plasma β-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease.
Wu G; Sankaranarayanan S; Wong J; Tugusheva K; Michener MS; Shi X; Cook JJ; Simon AJ; Savage MJ
J Neurosci Res; 2012 Dec; 90(12):2247-58. PubMed ID: 22987781
[TBL] [Abstract][Full Text] [Related]
14. Comparison of two different methods for measurement of amyloid-β peptides in cerebrospinal fluid after BACE1 inhibition in a dog model.
Borghys H; Jacobs T; Van Broeck B; Dillen L; Dhuyvetter D; Gijsen H; Mercken M
J Alzheimers Dis; 2014; 38(1):39-48. PubMed ID: 23948925
[TBL] [Abstract][Full Text] [Related]
15. S-Adenosylhomocysteine increases beta-amyloid formation in BV-2 microglial cells by increased expressions of beta-amyloid precursor protein and presenilin 1 and by hypomethylation of these gene promoters.
Lin HC; Hsieh HM; Chen YH; Hu ML
Neurotoxicology; 2009 Jul; 30(4):622-7. PubMed ID: 19635394
[TBL] [Abstract][Full Text] [Related]
16. Measurement of cellular beta-site of APP cleaving enzyme 1 activity and its modulation in neuronal assay systems.
Volbracht C; Penzkofer S; Mansson D; Christensen KV; Fog K; Schildknecht S; Leist M; Nielsen J
Anal Biochem; 2009 Apr; 387(2):208-20. PubMed ID: 19454261
[TBL] [Abstract][Full Text] [Related]
17. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment.
Zhong Z; Ewers M; Teipel S; Bürger K; Wallin A; Blennow K; He P; McAllister C; Hampel H; Shen Y
Arch Gen Psychiatry; 2007 Jun; 64(6):718-26. PubMed ID: 17548753
[TBL] [Abstract][Full Text] [Related]
18. A novel beta-site amyloid precursor protein cleaving enzyme (BACE) isoform regulated by nonsense-mediated mRNA decay and proteasome-dependent degradation.
Tanahashi H; Tabira T
Neurosci Lett; 2007 Nov; 428(2-3):103-8. PubMed ID: 17961921
[TBL] [Abstract][Full Text] [Related]
19. Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis.
Mattsson N; Axelsson M; Haghighi S; Malmeström C; Wu G; Anckarsäter R; Sankaranarayanan S; Andreasson U; Fredrikson S; Gundersen A; Johnsen L; Fladby T; Tarkowski A; Trysberg E; Wallin A; Anckarsäter H; Lycke J; Andersen O; Simon AJ; Blennow K; Zetterberg H
Mult Scler; 2009 Apr; 15(4):448-54. PubMed ID: 19153172
[TBL] [Abstract][Full Text] [Related]
20. Spirocyclic sulfamides as β-secretase 1 (BACE-1) inhibitors for the treatment of Alzheimer's disease: utilization of structure based drug design, WaterMap, and CNS penetration studies to identify centrally efficacious inhibitors.
Brodney MA; Barreiro G; Ogilvie K; Hajos-Korcsok E; Murray J; Vajdos F; Ambroise C; Christoffersen C; Fisher K; Lanyon L; Liu J; Nolan CE; Withka JM; Borzilleri KA; Efremov I; Oborski CE; Varghese A; O'Neill BT
J Med Chem; 2012 Nov; 55(21):9224-39. PubMed ID: 22984865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
